Cinnarizine Capsules
Function and Efficacy
This product is a piperazine calcium channel antagonist, which can prevent pathological calcium influx in smooth muscle cells of vascular walls and relieve vascular spasm. It has the effect of dilating cerebral and peripheral blood vessels, improving cerebral circulation and coronary circulation, especially for cerebral blood vessels. This product can also inhibit phosphodiesterase, prevent cAMP from decomposing into inactive 5prime;-AMP, thereby increasing the concentration of cAMP in cells, inhibiting the release of various biologically active substances such as histamine, 5-hydroxytryptamine, bradykinin, and also inhibiting the activation of complement C4. The lethal dose for humans is 100-500 mg/kg, and the LD50 (oral administration for mice and rats) is greater than 1g/kg.
Ingredients
The content of cinnarizine (C26H28N2) in this product should be 93.0% to 107.0% of the labeled amount.
| Name | Description | Content | CAS NO. | Manufacturer |
|---|---|---|---|---|
| StugeronIngredients |
This product is a piperazine calcium channel antagonist, which can prevent pathological calcium influx in smooth muscle cells of vascular walls and relieve vascular spasm. It has the effect of dilating cerebral and peripheral blood vessels, improving cerebral circulation and coronary circulation, especially for cerebral blood vessels. This product can also inhibit phosphodiesterase, prevent cAMP from decomposing into inactive 5prime;-AMP, thereby increasing the concentration of cAMP in cells, inhibiting the release of various biologically active substances such as histamine, 5-hydroxytryptamine, bradykinin, and also inhibiting the activation of complement C4. More |
298-57-7 | 15 |
Indication
Used for the treatment of cerebral thrombosis, cerebral embolism, cerebral arteriosclerosis, recovery period of cerebral hemorrhage, recovery period of subarachnoid hemorrhage, sequelae of brain trauma, inner ear vertigo, coronary artery sclerosis and diseases caused by poor peripheral circulation.
Usage and Dosage
Oral administration, 25-50 mg each time, 3 times a day.
Adverse Reactions
Common symptoms include drowsiness and fatigue. Some patients may experience weight gain (usually transient). Long-term use may occasionally cause depression and extrapyramidal reactions, such as involuntary movements and rigidity. A few patients may experience dry mouth, muscle pain, and rash.
Precautions
Patients with a history of allergy to this drug or a history of depression are contraindicated using this drug.
Drug Interactions
1. When used in combination with alcohol, hypnotics or sedatives, the sedative effect is aggravated. 2. When used in combination with phenytoin sodium and carbamazepine, the blood concentration of cinnarizine can be reduced.
Storage
Keep away from light and sealed.
Packaging Specification
25mg
Manufacturer
Guangzhou Yuhua Pharmaceutical Co., Ltd.
-
Founded in:
2012-09-20 -
Address:
Extraction and preparation workshop, No. 438, Guanghua 3rd Road, Baiyun District, Guangzhou -
Tax NO.:
91440101054513741Y -
Registered Funds:
50 million yuan -
Website:
-
Email: